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Abstract Biopharmaceuticals were copies of endogenous
human proteins developed in the mid-1990s that were
characterized by complex three-dimensional, high-
molecular weight compounds. What made them unique
was that contrary to classical chemotherapeutical drugs,
they were manufactured by living cells. One of these
biopharmaceuticals was granulocyte-colony stimulating
factor (G-CSF). Once their patent expired, generic versions
appeared in pharmacies. They are now called biosimilars.
There are several biosimilar G-CSFs approved in Europe:
Biograstim®/Filgrastim ratiopharm/Ratiograstim®/Teva-
grastim® (XM02); Zarzio® and Nivestim®. All these new
products are manufactured in facilities with state-of-the-art
technology. All products have passed the regulatory
requirements for approval, mainly phase I and phase III,
with the consequent PD/PK evaluations and studies on
efficacy and safety. However, there are still some concerns
regarding their long-term evaluation, in particular, the
limited experience at the time of approval of these products
in terms of efficacy, safety and immunogenicity. For this
reason, pharmacovigilance should be rigorous. A lot of
work remains to be done in terms of clarification with
regard to substituting a biosimilar G-CSF for the innovator
product and, finally, information must be provided to
physicians, pharmacists and patients to allow for proper
decision-making. Ultimately, only clinical trials and effective
post-marketing pharmacovigilance will provide definitive
evidence that a biosimilar is comparable to the originator-
reference product in terms of efficacy and safety.
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Introduction
By the mid-nineties, biopharmaceuticals were born, a new
generation of chemotherapeutical agents. They were copies
of endogenous human proteins characterized by complex
three-dimension, high-molecular- weight compounds. They
were made using either hybridoma or recombinant-DNA
technology. Among them were hematopoietic white blood
cell factors and, in particular, granulocytecolony stimulating
factor (G-CSF). What made them unique and different from
the classical chemotherapeutic agents was that were
manufactured by living cells. Biopharmaceuticals are
extremely similar one to another and to the reference
molecule, but are not identical, no matter how close their
similarities are.
Biopharmaceuticals are currently named “biosimilars” or
“follow-on-protein products” by the European (European
Medicines Agency) and the American regulatory agencies
(Food and Drug Administration) respectively.
G-CSF
G-CSF is a 20,000-Dalton glycoprotein composed of a
single polypeptide chain of 174 or 177 amino acids. It is
glycosylated at threonine residue 133. The native G-CSF is
encoded by a gene on chromosome 17 that encodes two
protein products due to differential splicing: isoform A of
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Isoform A differs from isoform B in that it contains an
additional three residues (Val-Ser-Gln) inserted after Leu35.
The 174-amino acid form is associated with greater
biological activity and stability than the longer isoform
and is the basis for commercial pharmaceutical G-CSF
products, including Neupogen® (filgrastim). G-CSF is the
most important hematopoietic growth factor for the recovery
of neutrophils. It stimulates the proliferation of neutropenic
progenitor cells and their differentiation to granulocytes, and
functionally activates mature neutrophils [1].
Mechanism of action
Endogenous G-CSF is a lineage-specific colony-stimulating
factor that is produced by monocytes, fibroblasts, and
endothelial cells. G-CSF regulates the production of
neutrophils within the bone marrow and affects neutrophil
progenitor proliferation, differentiation, and selected cell-
functional activation (including enhanced phagocytic ability,
priming of the cellular metabolism associated burst, antibody-
dependent killing, and the increased expression of some
functions associated with cell-surface antigens). G-CSF is not
species specific and has been shown to have minimal direct in
vivo or in vitro effects on the production of hematopoietic cell
types other than the neutrophil lineage.
It acts by binding to a specific transmembrane receptor
(G-CSF Receptor), a member of the class I cytokine
receptor family expressed on various hematopoietic cells
such as stem cells, multi-potent progenitors, myeloid-
committed progenitors, neutrophils, and monocytes. The
receptor forms homo-oligomeric complexes upon ligand
binding. The effects of G-CSF are mediated via a single
affinity class of receptors. The same mechanism of action
and receptor-mediated biological activity operates in the
mobilization of mature neutrophils into the circulating
neutrophil pool and acceleration of granulopoiesis.
Indications
Neupogen® (Filgrastim) is one of the first biopharmaceut-
ical human recombinant G-CSF products to be commer-
cialized and the reference drug upon which all biosimilar
G-CSFs have to be compared. It has been approved for the
following clinical conditions [1]:
& Reduction of the duration of neutropenia and the
incidence of febrile neutropenia in patients treated with
established cytotoxic chemotherapy for malignancy
(with the exception of chronic myelogenous leukemia
and myelodysplastic syndromes) and reduction in the
duration of neutropenia in patients undergoing myelo-
blastic therapy followed by bone marrow transplanta-
tion considered to be at increased risk of prolonged
severe neutropenia. This safety and efficacy of filgras-
tim are similar in adults and children receiving
cytotoxic chemotherapy.
& Mobilization of peripheral blood progenitor cells.
& In patients (children or adults) with severe congenital,
cyclic, or idiopathic neutropenia with an absolute neutro-
phil count (ANC) of 0,5×10
9/L, and a history of severe
or recurrent infections, long-term administration is
indicated to increase neutrophil counts and to reduce the
incidence and duration of infection-related events.
& Treatment of persistent neutropenia (ANC 1,0×10
9/L)
in patients with advanced HIV infection in order to
reduce the risk of bacterial infections when other
therapeutic options are inappropriate.
Biosimilar G-CSFs
Several biosimilar G-CSFs have been approved and will be
discussed in this chapter (Biograstim®/Filgrastim ratio-
pharm/Ratiograstim®/Tevagrastim® (XM02); Zarzio® and
Nivestim®).
Biograstim/filgrastim ratiopharm/ratiograstim/
tevagrastim (XM02)
Active substance
XM02 active substance is a recombinant human G-CSF
produced in E. coli, yielding a non-glycosylated protein
with an N-terminal methionyl extension (INN filgrastim).
The protein is expressed in inclusion bodies followed by
renaturation of protein and chromatographic purification
steps. The protein is a recombinant form of the 174 amino-
acid isoform that contains an additional N-terminal
methionine residue not found in the native human
protein. The naturally occurring G-CSF is glycosylated
at threonine residue 133, a modification that is absent in
the active XM02 compound as an E. coli expression
product [2, 3].
Presentation
The agent is supplied in pre-filled syringes containing
0.5 ml (for the lower strength) or 0.8 ml (for the higher
strength) of sterile, preservative-free solution for injection
consisting of 30 or 48 MIU (corresponding to 300 and
480 μg respectively). XM02 active substance together with
acidic sodium acetate buffer, sorbitol, polysorbate, and
water are used for injection. The formulation is similar to
Neupogen®, and only slight differences exist in the
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Administration is by subcutaneous or intravenous route,
normally at a dose of 1 to 10 μg/Kg/day depending on the
indication.
Clinical studies
Two phase I studies comparing to Neupogen® were
performed in healthy volunteers. Mean serum concentration
of 5 μg/Kg and 10 μg/Kg of the active compound of XM02
were similar to the ones of Neupogen®. One single
injection of the active XM02 compound produced the same
CD34+ cell count peak at 72 h and returned to base-line
levels after 336 h, exactly as for Neupogen®.
Clinical efficacy
Clinical efficacy was investigated in a pivotal study in
patients with breast cancer who were treated with the
reference product Neupogen® for up to four cycles of
chemotherapy. Clinical efficacy of XM02 was considered to
be comparable to Neupogen®. There were no immunoge-
nicity findings of clinical relevance, which had “major
consequences for efficacy and safety” in the three studies.
No antibody formation was identified.
Safety
Safety evaluations of XM02 have included analyses of five
clinical studies: two phase I studies with healthy volunteers
and three studies in cancer patients: breast cancer, lung
cancer or non-Hodgkin’s lymphoma. The lung cancer and
non-Hodgkin’s lymphoma studies were designed primarily
to investigate the safety of XM02. In a pooled analysis of
the three studies, the incidence of several treatment-
emergent adverse events (TEAEs) (in cycle 1: alopecia,
neutropenia, diarrhoea, asthenia, bone pain and abdominal
pain)werestatisticallysignificantlyhigherinthe Neupogen®-
only group than in the XM02-only group. However, these
differences are unlikely to be of clinical relevance (Tables 1
and 2).
Zarzio®
Filgrastim is produced by recombinant DNA technology
in bacteria (E. coli) from the full length human sequence
for N-(LMethionyl) granulocyte colony-stimulating factor
(r-metHuG-CSF). Native G-CSF is a glycosylated protein
but production in bacteria leads to a non-glycosylated
product; however, this is still biologically active. The
composition of Zarzio® is identical to the reference
product Neupogen® except for the buffer system. The
buffer for Zarzio® is glutamate and for Neupogen® it is
acetate [4].
Presentation
Two presentations of the medicinal product are provided:
30MU (300 μg/0.5 ml), solution for injection/concentration
for solution for infusion—pre-filled syringe; and 48 MU
(480 μg/0.5 ml), solution for injection/concentration for
solution for infusion—pre-filled syringe.
Clinical studies
Pharmakodynamic, pharmacokinetic studies
Four pharmakodynamic/pharmacokinetic (PK/PD) stud-
ies were performed in healthy volunteers. PD activity
was based primarily on ANC peak response and ANC
exposure, i.e., the whole AUC over 10 days. The results
of these studies support the comparability of the test
and reference products with respect to their pharmaco-
dynamic effect since absolute neutrophil count (ANC)
curves are superimposable whatever the route and the
dose. The CD34+ cell count after repeated dosing
(secondary PD endpoint) showed a similar time profile
for filgrastim and Neupogen® and AUEC0-216 h, PK.
Serum levels of free G-CSF were lower after the
administration of filgrastim than after that of Neupogen®;
the difference appeared consistent across the routes and
doses and was statistically significant. There was a
bioequivalence between the two products in terms of
Trade name Common name (INN) Biosimilar sponsor Reference product
Biograstim® Filgrastim CT Arzneimittel GmbH Neupogen®
Filgrastim ratiopharm® Filgrastim Ratiopharm GmbH Neupogen®
Ratiograstim® Filgrastim Ratiopharm GmbH Neupogen®
Tevagrastim® Filgrastim Teva Generics GmbH Neupogen®
Zarzio® Filgrastim Sandoz Neupogen®
Filgrastim HEXAL® Filgrastim Hexal Neupogen®
Nivestim® Filgrastim Hospira Neupogen®
Table 1 Approved biosimilars
G-CSF
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apparent difference in bioavailability may be overesti-
mated due to the non-linear saturable pharmacokinetics of
rhG-CSF, which is eliminated for a large part through binding
to its target cells, neutrophils, and myeloid progenitors.
Indeed,thedifferenceineliminationcharacteristicsatdifferent
doses may be related to the fact that receptor-mediated
clearance (which is saturable) is predominant at lower doses,
while renal clearance becomes more important at higher
doses.
Efficacy
The comparability of the efficacy based on a study in
healthy volunteers (absolute neutrophile and CD34+ cell
counts) was considered acceptable by the Committee for
Medicinal Products for Human Use (CHMP). Furthermore,
the extrapolation to all indications of the reference products
is acceptable since the mechanism of action is the same;
i.e., direct stimulation of bone marrow cells through one
specific type of surface receptor.
Safety
A direct comparison of the safety profile of the test and
reference product was possible based on a total of four
studies involving 146 healthy volunteers. ADRs associ-
ated with filgrastim were consistent with those reported
in normal donors as described for Neupogen®. Overall,
these data supported the comparability of the products.
The small single arm trial in cancer patients submitted
allowed, to a certain extent, ruling out unexpected
safety issues and suggested low immunogenicity of the
test product. Additional long-term safety and immuno-
genicity data will be collected post-marketing (see
Tables 1 and 2).
Table 2 European public assessment reports comparison—filgrastim
Zarzio/filgrastim hexal Biograstim/filgrastim ratiopharm/
ratiograstim/tevagrastim (XM02)
Nivestim
Product characteristics
Produced E. Coli E. Coli E. Coli
Strength Two strengths: 30 MU/0.5 ml and
48 MU/0.5 ml.
Two strengths: 30 or 48 MIU
(corresponding to 300 and 480 μg
respectively).
Three strengths: 120 μg/0.2 ml,
300 μg/0.5 ml and 480 μg/
0.5 ml.
Medicinal
product
Product composition of Zarzio and
Neupogen® are quantitatively
identical except the buffer system,
glutamate for Zarzio and acetate for
Neupogen®
Buffered with acetate. Differs from
Neupogen® only in pH and in the
concentration of filgrastim and
polysorbate 80.
Buffered with acetate.
Pre-clinical data
Studies 6 primary PD studies (4 in vitro); 3
toxicology studies (comparative
repeat-dose toxicity, toxicokinetics,
local tolerance; no single-dose
toxicity study); no secondary PD
studies; no safety pharmacology
studies; no PK studies
6 primary PD studies (3 in vitro); 1
secondary PD study (in vitro); 3 safety
pharmacology studies; 2 PK studies; 6
toxicology studies (repeat dose toxicity
study non-comparative)
Primary PD studies: PD response
was determined in a neutropenic
rat model, as well as in healthy rat
in a repeat-dose toxicity study; no
secondary PD studies; no safety
pharmacology studies; PK
assessed as part of the repeat-dose
toxicity study; no single-dose
toxicity study
Clinical data
Phase I (PK/PD)
studies
4 PK/PD studies in healthy volunteers 2 PK/PD studies in healthy volunteers 2 PK/PD studies in healthy
voluteers
Phase III studies 1 non-controlled study in patients with
breast cancer
3 RCTS (patients with breast cancer, lung
cancer, NHL)
1 RCT in patients with breast
cancer
Efficacy data Similar to Neupogen® The
comparability of the efficacy based
on a PPD study in healthy volunteers
(absolute neutrophile and CS34+ cell
counts) was considered acceptable
by the CHMP.
Similar to Neupogen® There were no
statistically significant differences
between XM02 and Neupogen® with
regard to the mean ANC nadir and with
regard to time to ANC recovery in the
studies.
Similar to Neupogen® There was
therapeutic equivalence between
the two products in terms of
efficacy with regard to the mean
ANC nadir and with regard to
time to ANC recovery.
Safety data Similar to Neupogen® Similar to Neupogen® Similar to Neupogen®
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Introduction
Nivestim® (also referred to as Pliva/Mayne filgrastim) is a
175-amino acid protein recombinant methionyl human
granulocyte-colony stimulating factor (r-metHuG-CSF) that
is produced in E. coli and has a molecular weight of
18,800 Da. Unlike the human protein, Nivestim® is
unglycosylated and contains an N-terminal methionine.
Filgrastim, the active substance of Nivestim® is a recom-
binant human G-CSF produced in E. coli as a non-
glycosylated protein containing an N-terminal methionyl
extension. It stimulates the proliferation, differentiation, and
activation of late progenitor cells of the granulocyte
lineage, as well as enhances the activity of mature
neutrophils [5].
Presentation
Nivestim solution for injection or infusion comes in three
strengths: 120 μg/0.2 ml, 300 μg/0.5 ml, and 480 μg/
0.5 ml. The qualitative and quantitative composition of
Nivestim® and Neupogen® is the same, with the exception
of the 120 μg/0.2 ml presentation, which is not marketed by
Amgen. However, this presentation only differs in fill
volume from the 300 μg/0.5 ml presentation.
Clinical studies
Two PD/PK studies were performed in healthy volun-
teers. Two phase I trials were carried out to study
pharmacokinetics (PK) and demonstrate biosimilarity
between Nivestim® and Neupogen®, the reference
product. The primary endpoint ANC AUC was also
equivalent with both IV and SC administration compared
to Neupogen®. Results show that the mean ANC max,
ANCmin, and CD34+ were equivalent for patients
receiving both Nivestim® and Neupogen®, and ANC
Tmax occurred slightly earlier following treatment with
Nivestim® (7.845 h) compared to treatmentwithNeupogen ®
(9.448 h).
Efficacy
Its efficacy is similar to Neupogen®. The clinical program
for demonstrating biosimilarity between Nivestim® and
Neupogen® included one phase III study, which was
conducted in patients with breast cancer who received
G-CSF prophylaxis in addition to a normal chemotherapy.
There was therapeutic equivalence between the two
products in terms of efficacy with regard to the mean
ANC nadir and with regard to time to ANC recovery.
Safety
Safety is similar to Neupogen®. The Nivestim® study
group showed a greater proportion of patients with severe
neutropenia than the Neupogen® study group in cycle 1
(77.6% versus 68.2%) and cycle 2. A lower proportion of
Nivestim® patients experienced severe neutropenia in cycle
3 compared with that of Neupogen® patients. Duration of
severe neutropenia was longer in the Nivestim study group.
These findings were not statistically significant. The most
common individual adverse reaction was bone pain; there
was a higher incidence of bone pain in the Nivestim® group
(Nivestim: n=26, 14.2%; Neupogen: n=9, 9.5%). All of
these events were mild or moderate in nature except that
involving one patient on Neupogen® who had severe pain
in the extremity (see Tables 1 and 2).
Summary
Biosimilar G-CSF (Biograstim/Filgrastim ratiopharm/Ratio-
grastim/Tevagrastim (XM02); Zarzio and Nivestim) are
manufactured in facilities with state-of-the-art technology.
All products have passed the regulatory requirements for
approval [6], mainly phase I and a phase III, with the
consequent PD/PK evaluations and studies on efficacy and
safety. However, as it has been largely discussed in this
issue of Targeted Oncology, there are still some concerns for
the long-term evaluation of these products, in particular, the
limited experience at the time of approval of these products
in terms of efficacy, safety, and immunogenicity. For this
same reason, pharmacovigilance should be rigorous and is
important as a public health concern. Guidelines will allow
extrapolation of data to additional indications, for example,
pediatric indication and PBPC in healthy donors. A lot
of work remains to be done in terms of clarification
with regard to substituting a biosimilar G-CSF for the
innovator product and, finally, information must be
provided to physicians, pharmacists, and patients to
allow for proper decision-making. Ultimately, only
clinical trials and effective post-marketing pharmacovi-
gilance will provide definitive evidence that a biosimilar
is comparable to the reference product in terms of
efficacy and safety [7].
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